The Senescence Associated Secretory Phenotype as a Basis for an Aging Clock

Key Takeaways

• SASP Score derived from UK Biobank proteomics predicts mortality risk
• Deep‑learning autoencoder integrates curated SASP proteins for robust scoring
• Score correlates with incidence of dementia, COPD, heart attack, stroke
• Exercise intervention altered SASP Score trajectory over 18 months in trial

Pulse Analysis

Cellular senescence, the irreversible arrest of damaged cells, accumulates with age and drives chronic inflammation through the senescence‑associated secretory phenotype (SASP). Traditional biomarkers have struggled to capture the systemic impact of these cells, limiting clinicians' ability to gauge biological age versus chronological age. By measuring a panel of SASP proteins in blood, scientists can now infer the body‑wide senescent cell load, offering a more direct window into the aging process and its disease‑related sequelae.

The new SASP Score leverages a guided autoencoder with Transformer architecture (GAET) trained on the UK Biobank Pharma Proteomics Project, one of the world’s largest protein datasets. Researchers first curated a list of biologically relevant SASP proteins, then used semi‑supervised deep learning to compress and weight the proteomic signals into a single composite metric. Internal analyses demonstrated that higher scores strongly predict all‑cause mortality and the onset of conditions such as dementia, chronic obstructive pulmonary disease, myocardial infarction, and stroke, independent of traditional risk factors. An independent clinical trial further validated the score, showing that a structured 18‑month multimodal exercise regimen could meaningfully shift SASP trajectories.

For investors, biotech firms, and healthcare providers, the SASP Score represents a scalable tool for risk stratification and therapeutic monitoring. It could accelerate the development of senolytic drugs by providing a quantifiable endpoint, while also informing personalized lifestyle interventions aimed at reducing senescent burden. As the field moves toward precision geroscience, blood‑based aging clocks like this one may become integral to preventive medicine, insurance underwriting, and longevity research, reshaping how we assess and intervene in age‑related disease.